Few people starting tamoxifen saw an eye doctor in the first year

Design

Retrospective cohort

Population

2,327 adults starting tamoxifen; 2,809 on aromatase inhibitors for comparison

Primary outcome

Any ophthalmic encounter within 12 months

Effect

7.0% any encounter; 1.7% retinal imaging; adjusted OR vs AI 1.10

Using US research cohort data, this study followed 2,327 people starting tamoxifen for a year. Only 7.0% had any eye encounter and 1.7% had retinal imaging. Those with existing glaucoma or diabetic retinopathy were far more likely to be seen (25.0% vs 6.3%).

Among those with breast cancer, eye care use after tamoxifen was no higher than after aromatase inhibitors once adjusted (OR 1.10).

Tamoxifen retinopathy is uncommon and no formal screening guideline exists, so this does not show that people are being harmed. It does show that new visual symptoms on tamoxifen are unlikely to be picked up unless patients are told to report them.

• Tell patients starting tamoxifen to report new blurred or distorted vision
• Consider a baseline eye check for patients with existing retinal disease
• Ask about visual symptoms at oncology reviews
• Include tamoxifen in the drug history when assessing unexplained maculopathy

Why it matters

Without a screening guideline, detection of tamoxifen retinopathy relies on patients knowing what to report.

Don't overread it

It measures eye care use, not how often tamoxifen damages the retina.

The statistics, in plain English

7% means about 1 in 14 had any eye visit in a year. The comparison with aromatase inhibitors shows tamoxifen did not prompt more eye care.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.